Lan Huang

Prior to founding BeyondSpring, Dr. Huang co-founded Wuxi MTLH Biotechnology Co. Ltd., in 2007, where she served as Chief Executive Officer since 2010 and whose self-designed cancer peptide drug’s China rights were acquired in 2010 by Shanghai Pharmaceutical Group, one of the top three pharmaceutical companies in China. She also co-founded Paramax International in 2008, which was sold to RPS (a global CRO), then to Warburg Pincus in 2011. In 2010, Dr. Huang founded Wanchun Biotech. Her translational research in cancer signaling pathways involving Ras was published in two Nature papers. In addition, Dr. Huang worked with Forward Ventures, where she led partnering initiatives between Forward’s portfolio companies and Chinese pharmaceutical companies. Dr. Huang was trained at Memorial Sloan Kettering Cancer Center from 1998 to 2002, where her breakthrough research in solving the first E2-E3 ubiquitin ligase structure involving P53 degradation was published in Science following 10 months of preparation. She serves as Director of Wuxi MTLH Biotechnology Co. Ltd. The immense importance of this field is illustrated by the 2005 award of the Nobel Prize in Chemistry to the founders of ubiquitin-mediated protein degradation. She has invented and holds patents for a number of biotech products for oncology and dermatology indications. In 2009, she was the recipient of China’s “Thousand Talent Innovator Award.” She received her Ph.D. in Chemistry in four-and-a-half years from the University of California at Berkeley, where she won the graduating Ph.D. woman award from Soroptimist International. Her translational research in cancer signaling pathways involving Ras was published in two Nature papers. Dr. Huang received her B.A., Magna Cum Laude and Phi Beta Kappa, from Lawrence University, where she served as a trustee from 2012 to 2015. She also studied at Fudan University in Shanghai, China.